Our research teams have made significant basic science contributions to the study of infectious disease-causing organisms and are paving the way for new therapies.
A University at Buffalo training program that aims to address the nation’s shortage of clinician-scientists has been recognized by the National Institutes of Health (NIH).
The University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) has awarded six life sciences companies a total of $253,000 to support new biomedical technologies.
As public health experts cautiously anticipate how COVID-19 will play out this fall, Michael W. Russell, PhD, professor emeritus of microbiology and immunology, is reiterating that substantial immunity against the SARS-CoV-2 virus will only happen with a vaccine that can be delivered through the nose.
Developing a more effective vaccine for tuberculosis is the goal of research led by Jonathan F. Lovell, PhD, SUNY Empire Innovation Associate Professor of biomedical engineering, that has been funded by the National Institutes of Health.
Disease progression modeling of bladder cancer. Yijun Sun (Co-Principal Investigator). NIH. $2,500,000. 9/1/2022-8/1/2027.
Host and microbial risk factors of oral thrush in cancer patients receiving chemotherapy. Yijun Sun (Co-Investigator). NIH. $4,100,000. 7/1/2022-6/1/2027.
Protist Oxygen Sensing in Human Disease. Ira Blader (Co-Principal Investigator). NIH/NIAID. $3,190,179. 7/1/2022-6/1/2027.